See more : AgileThought, Inc. (AGIL) Income Statement Analysis – Financial Results
Complete financial analysis of Theravance Biopharma, Inc. (TBPH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Theravance Biopharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Central Pattana Public Company Limited (CPN.BK) Income Statement Analysis – Financial Results
- Hallenstein Glasson Holdings Limited (HLG.NZ) Income Statement Analysis – Financial Results
- ICON Public Limited Company (ICLR) Income Statement Analysis – Financial Results
- Nisshinbo Holdings Inc. (3105.T) Income Statement Analysis – Financial Results
- ThinTech Materials Technology Co., Ltd. (3663.TWO) Income Statement Analysis – Financial Results
Theravance Biopharma, Inc. (TBPH)
About Theravance Biopharma, Inc.
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; Nezulcitinib, a lung-selective, nebulized JAK inhibitor, which is in Phase II clinical development for the potential treatment of hospitalized patients with acute lung injury caused by COVID-19; Inhaled ALK5i, a potential inhaled anti-fibrotic agent that is in Phase I for the treatment of idiopathic pulmonary fibrosis; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY for the treatment of COPD and asthma; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Viatris Inc., Janssen Biotech, Inc., Alfasigma S.p.A, and Takeda Pharmaceutical Company Limited. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 57.42M | 51.35M | 55.31M | 71.86M | 73.41M | 60.37M | 15.39M | 48.65M | 42.13M | 11.69M | 226.00K | 130.15M | 14.85M |
Cost of Revenue | 40.62M | 6.59M | 7.29M | 260.95M | 219.25M | 715.00K | 6.03M | 2.89M | 4.66M | 4.06M | 120.58M | 114.00M | 3.84M |
Gross Profit | 16.80M | 44.76M | 48.03M | -189.10M | -145.83M | 59.66M | 9.36M | 45.75M | 37.47M | 7.63M | -120.35M | 16.15M | 11.01M |
Gross Profit Ratio | 29.26% | 87.17% | 86.83% | -263.16% | -198.65% | 98.82% | 60.81% | 94.05% | 88.95% | 65.28% | -53,253.54% | 12.41% | 74.12% |
Research & Development | 40.62M | 63.39M | 193.66M | 260.95M | 219.25M | 201.35M | 173.89M | 141.71M | 129.17M | 168.52M | 120.58M | 114.00M | 98.85M |
General & Administrative | 65.00M | 59.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Selling & Marketing | 5.10M | 8.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 70.10M | 67.07M | 99.30M | 108.66M | 106.08M | 97.06M | 95.59M | 84.51M | 90.20M | 71.65M | 35.93M | 25.73M | 21.50M |
Other Expenses | 0.00 | 0.00 | 0.00 | -1.61M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | 113.46M | 130.47M | 292.95M | 369.61M | 325.33M | 298.41M | 269.48M | 226.22M | 219.37M | 240.17M | 156.51M | 139.72M | 120.35M |
Cost & Expenses | 113.46M | 130.47M | 292.95M | 369.61M | 325.33M | 299.12M | 275.51M | 229.12M | 224.03M | 244.23M | 156.51M | 139.72M | 124.19M |
Interest Income | 9.12M | 8.55M | 1.11M | 2.83M | 8.40M | 11.97M | 4.96M | 1.31M | 631.00K | 1.87M | 0.00 | 0.00 | 0.00 |
Interest Expense | 2.35M | 6.37M | 46.89M | 44.59M | 31.86M | 10.48M | 8.55M | 1.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 6.05M | 6.59M | 7.29M | 6.64M | 6.52M | 3.17M | 4.03M | 3.12M | 2.99M | 2.66M | 2.65M | 3.25M | 3.84M |
EBITDA | -40.87M | -79.86M | -249.39M | -294.00M | -203.29M | -212.44M | -259.14M | -176.04M | -178.77M | -228.01M | -153.63M | -6.32M | -105.49M |
EBITDA Ratio | -71.17% | -137.45% | -239.64% | -315.19% | -285.80% | -357.14% | -1,658.42% | -368.27% | -424.70% | -1,989.55% | -67,978.32% | -4.86% | -710.19% |
Operating Income | -56.04M | -91.96M | -257.78M | -297.76M | -251.92M | -238.75M | -260.12M | -180.47M | -181.90M | -232.54M | -156.28M | -9.58M | -109.34M |
Operating Income Ratio | -97.58% | -179.09% | -466.06% | -414.37% | -343.14% | -395.48% | -1,690.65% | -370.96% | -431.80% | -1,989.55% | -69,152.21% | -7.36% | -736.06% |
Total Other Income/Expenses | 6.77M | -858.00K | -7.44M | 11.22M | 10.24M | 12.67M | -11.59M | -92.00K | 631.00K | 1.87M | 0.00 | 0.00 | 0.00 |
Income Before Tax | -49.27M | -92.82M | -199.58M | -286.54M | -241.68M | -226.09M | -271.71M | -180.56M | -181.27M | -230.67M | -156.28M | -9.58M | -109.34M |
Income Before Tax Ratio | -85.80% | -180.76% | -360.83% | -398.76% | -329.20% | -374.50% | -1,765.96% | -371.15% | -430.30% | -1,973.60% | -69,152.21% | -7.36% | -736.06% |
Income Tax Expense | 5.92M | 9.00K | -151.00K | -8.52M | -5.22M | -10.56M | 13.69M | 10.11M | 951.00K | 6.36M | 0.00 | 0.00 | 0.00 |
Net Income | -55.19M | -92.82M | -199.43M | -278.02M | -236.46M | -215.52M | -285.41M | -190.67M | -182.22M | -237.04M | -156.28M | -9.58M | -109.34M |
Net Income Ratio | -96.11% | -180.78% | -360.55% | -386.90% | -322.08% | -357.01% | -1,854.97% | -391.94% | -432.56% | -2,028.05% | -69,152.21% | -7.36% | -736.06% |
EPS | -1.00 | -1.26 | -2.87 | -4.46 | -4.25 | -3.99 | -5.45 | -4.26 | -5.34 | -7.46 | -4.92 | -0.30 | -3.43 |
EPS Diluted | -1.00 | -1.26 | -2.87 | -4.46 | -4.25 | -3.99 | -5.45 | -4.26 | -5.34 | -7.46 | -4.84 | -0.30 | -3.43 |
Weighted Avg Shares Out | 55.30M | 73.59M | 69.46M | 62.35M | 55.61M | 53.97M | 52.35M | 44.71M | 34.15M | 31.76M | 31.74M | 31.74M | 31.90M |
Weighted Avg Shares Out (Dil) | 55.30M | 73.59M | 69.46M | 62.35M | 55.61M | 53.97M | 52.35M | 44.71M | 34.15M | 31.76M | 32.26M | 32.26M | 31.90M |
Theravance Biopharma to Participate in the 6th Annual Evercore ISI HealthCONx Conference
Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
Theravance's (TBPH) Q3 Loss Narrows, Revenues Beat Marginally
Theravance Biopharma, Inc. (TBPH) Q3 2023 Earnings Call Transcript
Theravance Biopharma, Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update
Theravance Biopharma to Report Third Quarter 2023 Financial Results on November 7, 2023
Theravance: Positive Findings Boost Ampreloxetine Development
Theravance Biopharma: YUPELRI Numbers Don't Substantiate 9x Forward Sales, Rate Hold
Theravance Biopharma to Participate in an Upcoming Investor Conference
Source: https://incomestatements.info
Category: Stock Reports